eduKateSG · Why Science?
Recognise a report, start the right clock and preserve enough context for responsible post-approval decisions
Read FDA’s final March 2026 E2D(R1) guidance through spontaneous and solicited reports, digital platforms, minimum criteria, day zero, seriousness, expectedness, duplicates, follow-up and privacy.
After approval, safety information can arrive from a clinician, a patient, a call centre, a research programme, market research or a social-media space. The scientific challenge is to recognise what kind of report it is, preserve the context and act within the applicable reporting framework.
FDA’s final March 2026 ICH E2D(R1) guidance updates the 2003 framework for managing and reporting post-approval ICSRs. It clarifies newer sources such as social media, market research programmes, patient support programmes and organised data collection systems.
Did you know? A report found on a company product website may be spontaneous, while an event found through an organised digital data-collection activity can be solicited. Source context changes how the case is managed.
For students, E2D(R1) is a lesson in classification, evidence and time. Clear definitions help teams avoid both missed reports and inflated certainty.
Chapter index
Chapters 1–9: March 2026 final guidance, adverse events, adverse reactions, minimum criteria and valid ICSRs
- 1. E2D(R1) governs post-approval case management
- 2. The March 2026 guidance is final Level 1
- 3. A valid ICSR needs minimum information
- 4. Adverse event and adverse reaction are distinct
- 5. Spontaneous reports arise without organised solicitation
- 6. Solicited reports come from organised systems
- 7. Digital platforms require defined responsibilities
- 8. Day zero starts when reportability can be recognised
- 9. Seriousness follows outcomes and medical importance
Chapters 10–17: spontaneous and solicited sources, digital platforms, day zero, reporting, follow-up and quality
- 10. Expectedness uses the relevant reference
- 11. Special situations may carry safety information
- 12. Literature surveillance needs reproducible methods
- 13. Duplicates can distort the safety picture
- 14. Follow-up should improve clinically important gaps
- 15. Privacy and verification must work together
- 16. Quality systems keep vendors and programmes aligned
- 17. A complete E2D(R1) receipt makes the decision reproducible
The guidance harmonises definitions and standards for managing and reporting individual safety cases after a medicinal product is approved. It addresses spontaneous reports, solicited reports and contemporary data sources while supporting consistent regional pharmacovigilance.
The core discipline in e2d(r1) governs post-approval case management is to preserve source context while acting on time. The guidance harmonises definitions and standards for managing and reporting individual safety cases after a medicinal product is approved. It addresses spontaneous reports, solicited reports and contemporary data sources while supporting consistent regional pharmacovigilance. Keep this boundary visible: National laws and regional rules determine specific reporting obligations and timelines.
Try this
Classify five source scenarios for e2d(r1) governs post-approval case management. Record product, country, approval status, source and applicable rule before processing. Explain what changes the result. Keep this limit: National laws and regional rules determine specific reporting obligations and timelines.
A strong science note separates observation from interpretation. Record product, country, approval status, source and applicable rule before processing. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Record product, country, approval status, source and applicable rule before processing. Keep this boundary visible: National laws and regional rules determine specific reporting obligations and timelines.
FDA lists E2D(R1) as final Level 1 guidance dated March 2026 under docket FDA-2024-D-0803, issued by CDER and CBER. It replaces both the March 2024 draft and the September 2003 final guidance.
For the march 2026 guidance is final level 1, a valid case and a proven causal relationship are different conclusions. FDA lists E2D(R1) as final Level 1 guidance dated March 2026 under docket FDA-2024-D-0803, issued by CDER and CBER. It replaces both the March 2024 draft and the September 2003 final guidance. Preserve this guardrail: Legacy procedures should not be assumed current after a superseding final guidance.
Try this
Build a day-zero timeline for the march 2026 guidance is final level 1. Create a controlled implementation record mapping every revised concept to procedure and training. Include vendor and digital-platform handoffs. Respect this boundary: Legacy procedures should not be assumed current after a superseding final guidance.
A strong science note separates observation from interpretation. Create a controlled implementation record mapping every revised concept to procedure and training. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Create a controlled implementation record mapping every revised concept to procedure and training. Keep this boundary visible: Legacy procedures should not be assumed current after a superseding final guidance.
Case validity generally depends on an identifiable reporter, an identifiable patient, a suspected medicinal product and an adverse event or reaction. Identifiable does not require public disclosure of personal details; it means enough information exists to recognise a real reporter and patient.
A defensible decision about a valid icsr needs minimum information records what was known, when it was known and which rule applied. Case validity generally depends on an identifiable reporter, an identifiable patient, a suspected medicinal product and an adverse event or reaction. Identifiable does not require public disclosure of personal details; it means enough information exists to recognise a real reporter and patient. Remember: A partially described case may still require follow-up even before all criteria are met.
Try this
Audit one post-approval case for a valid icsr needs minimum information. Document which minimum criteria are present, their sources and the follow-up plan for missing elements. Prioritise follow-up by decision value. Preserve this caution: A partially described case may still require follow-up even before all criteria are met.
A strong science note separates observation from interpretation. Document which minimum criteria are present, their sources and the follow-up plan for missing elements. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Document which minimum criteria are present, their sources and the follow-up plan for missing elements. Keep this boundary visible: A partially described case may still require follow-up even before all criteria are met.
An adverse event is an untoward occurrence temporally associated with product use, while an adverse reaction reflects at least a suspected causal relationship in the relevant reporting context. Careful wording prevents observation from being presented as proof.
The core discipline in adverse event and adverse reaction are distinct is to preserve source context while acting on time. An adverse event is an untoward occurrence temporally associated with product use, while an adverse reaction reflects at least a suspected causal relationship in the relevant reporting context. Careful wording prevents observation from being presented as proof. Keep this boundary visible: Reporter attribution and company assessment can differ and both may need preservation.
Try this
Classify five source scenarios for adverse event and adverse reaction are distinct. Separate verbatim facts, reporter causality and company causality in the case record. Explain what changes the result. Keep this limit: Reporter attribution and company assessment can differ and both may need preservation.
A strong science note separates observation from interpretation. Separate verbatim facts, reporter causality and company causality in the case record. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Separate verbatim facts, reporter causality and company causality in the case record. Keep this boundary visible: Reporter attribution and company assessment can differ and both may need preservation.
CHAPTER 5 OF 17 · Classify the source
5. Spontaneous reports arise without organised solicitation
A spontaneous communication is made voluntarily by a healthcare professional, consumer or other person and is not derived from an organised data-collection system. Reports on company-controlled websites can remain spontaneous when people post them without a structured collection activity.
For spontaneous reports arise without organised solicitation, a valid case and a proven causal relationship are different conclusions. A spontaneous communication is made voluntarily by a healthcare professional, consumer or other person and is not derived from an organised data-collection system. Reports on company-controlled websites can remain spontaneous when people post them without a structured collection activity. Preserve this guardrail: The digital location alone does not determine source classification.
Try this
Build a day-zero timeline for spontaneous reports arise without organised solicitation. Describe what prompted the report and whether the company asked structured safety questions. Include vendor and digital-platform handoffs. Respect this boundary: The digital location alone does not determine source classification.
A strong science note separates observation from interpretation. Describe what prompted the report and whether the company asked structured safety questions. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Describe what prompted the report and whether the company asked structured safety questions. Keep this boundary visible: The digital location alone does not determine source classification.
CHAPTER 6 OF 17 · Classify the source
6. Solicited reports come from organised systems
Clinical studies, registries, patient support programmes, market research and other organised data collection systems can generate solicited reports. Their handling depends on the system’s design and documented causality approach.
A defensible decision about solicited reports come from organised systems records what was known, when it was known and which rule applied. Clinical studies, registries, patient support programmes, market research and other organised data collection systems can generate solicited reports. Their handling depends on the system’s design and documented causality approach. Remember: A programme label is insufficient; the actual collection method determines classification.
Try this
Audit one post-approval case for solicited reports come from organised systems. Attach the programme protocol or data-collection description to the case-source decision. Prioritise follow-up by decision value. Preserve this caution: A programme label is insufficient; the actual collection method determines classification.
A strong science note separates observation from interpretation. Attach the programme protocol or data-collection description to the case-source decision. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Attach the programme protocol or data-collection description to the case-source decision. Keep this boundary visible: A programme label is insufficient; the actual collection method determines classification.
CHAPTER 7 OF 17 · Classify the source
7. Digital platforms require defined responsibilities
Companies need procedures for safety information on digital platforms under their responsibility. E2D(R1) distinguishes unsolicited posts from organised digital data collection and ties review and reporting to access, minimum criteria and source context.
The core discipline in digital platforms require defined responsibilities is to preserve source context while acting on time. Companies need procedures for safety information on digital platforms under their responsibility. E2D(R1) distinguishes unsolicited posts from organised digital data collection and ties review and reporting to access, minimum criteria and source context. Keep this boundary visible: Teams are not expected to treat the entire internet as a company-controlled safety inbox.
Try this
Classify five source scenarios for digital platforms require defined responsibilities. Create an inventory of owned, sponsored and monitored platforms with review frequency and escalation paths. Explain what changes the result. Keep this limit: Teams are not expected to treat the entire internet as a company-controlled safety inbox.
A strong science note separates observation from interpretation. Create an inventory of owned, sponsored and monitored platforms with review frequency and escalation paths. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Create an inventory of owned, sponsored and monitored platforms with review frequency and escalation paths. Keep this boundary visible: Teams are not expected to treat the entire internet as a company-controlled safety inbox.
CHAPTER 8 OF 17 · Classify the source
8. Day zero starts when reportability can be recognised
The regulatory clock begins when the marketing authorisation holder or a third party acting for it has sufficient information to determine that minimum reporting criteria are met. For accessed digital data, day zero may differ from the date the content was created or first accessed.
For day zero starts when reportability can be recognised, a valid case and a proven causal relationship are different conclusions. The regulatory clock begins when the marketing authorisation holder or a third party acting for it has sufficient information to determine that minimum reporting criteria are met. For accessed digital data, day zero may differ from the date the content was created or first accessed. Preserve this guardrail: Delaying internal routing does not reset the clock.
Try this
Build a day-zero timeline for day zero starts when reportability can be recognised. Capture receipt, access, recognition and escalation timestamps with responsible persons. Include vendor and digital-platform handoffs. Respect this boundary: Delaying internal routing does not reset the clock.
A strong science note separates observation from interpretation. Capture receipt, access, recognition and escalation timestamps with responsible persons. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Capture receipt, access, recognition and escalation timestamps with responsible persons. Keep this boundary visible: Delaying internal routing does not reset the clock.
CHAPTER 9 OF 17 · Manage the clock
9. Seriousness follows outcomes and medical importance
Death, immediate life threat, hospitalisation or prolongation, significant disability, congenital anomaly and other medically important conditions can make a case serious. Severity describes intensity and should not be confused with seriousness.
A defensible decision about seriousness follows outcomes and medical importance records what was known, when it was known and which rule applied. Death, immediate life threat, hospitalisation or prolongation, significant disability, congenital anomaly and other medically important conditions can make a case serious. Severity describes intensity and should not be confused with seriousness. Remember: A severe symptom may be non-serious, and a modest symptom may be serious because of its outcome.
Try this
Audit one post-approval case for seriousness follows outcomes and medical importance. Map each case independently to seriousness criteria and intensity. Prioritise follow-up by decision value. Preserve this caution: A severe symptom may be non-serious, and a modest symptom may be serious because of its outcome.
A strong science note separates observation from interpretation. Map each case independently to seriousness criteria and intensity. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Map each case independently to seriousness criteria and intensity. Keep this boundary visible: A severe symptom may be non-serious, and a modest symptom may be serious because of its outcome.
Expectedness compares the reported reaction with the appropriate product information under the applicable regional framework. Greater specificity or severity can make known information meaningfully different.
The core discipline in expectedness uses the relevant reference is to preserve source context while acting on time. Expectedness compares the reported reaction with the appropriate product information under the applicable regional framework. Greater specificity or severity can make known information meaningfully different. Keep this boundary visible: Expectedness is a regulatory comparison, not a prediction about what clinicians should have anticipated.
Try this
Classify five source scenarios for expectedness uses the relevant reference. Record the reference document, version, effective date and exact comparison. Explain what changes the result. Keep this limit: Expectedness is a regulatory comparison, not a prediction about what clinicians should have anticipated.
A strong science note separates observation from interpretation. Record the reference document, version, effective date and exact comparison. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Record the reference document, version, effective date and exact comparison. Keep this boundary visible: Expectedness is a regulatory comparison, not a prediction about what clinicians should have anticipated.
CHAPTER 11 OF 17 · Manage the clock
11. Special situations may carry safety information
Pregnancy, breastfeeding, overdose, misuse, abuse, medication error, occupational exposure and lack of efficacy can require collection and evaluation even when no adverse event is initially described. Follow-up should be proportionate to possible clinical importance.
For special situations may carry safety information, a valid case and a proven causal relationship are different conclusions. Pregnancy, breastfeeding, overdose, misuse, abuse, medication error, occupational exposure and lack of efficacy can require collection and evaluation even when no adverse event is initially described. Follow-up should be proportionate to possible clinical importance. Preserve this guardrail: A special situation is not automatically an adverse reaction or reportable case in every region.
Try this
Build a day-zero timeline for special situations may carry safety information. Use a decision tree that preserves the situation while checking regional reporting rules. Include vendor and digital-platform handoffs. Respect this boundary: A special situation is not automatically an adverse reaction or reportable case in every region.
A strong science note separates observation from interpretation. Use a decision tree that preserves the situation while checking regional reporting rules. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Use a decision tree that preserves the situation while checking regional reporting rules. Keep this boundary visible: A special situation is not automatically an adverse reaction or reportable case in every region.
CHAPTER 12 OF 17 · Manage the clock
12. Literature surveillance needs reproducible methods
Published scientific and medical literature can contain reportable cases or relevant safety information. Search strategy, frequency, product attribution, duplicate checking and article access determine whether cases are recognised consistently.
A defensible decision about literature surveillance needs reproducible methods records what was known, when it was known and which rule applied. Published scientific and medical literature can contain reportable cases or relevant safety information. Search strategy, frequency, product attribution, duplicate checking and article access determine whether cases are recognised consistently. Remember: A citation alone may not provide the minimum information needed for a valid ICSR.
Try this
Audit one post-approval case for literature surveillance needs reproducible methods. Keep search strings, dates, review decisions, full-text status and case links. Prioritise follow-up by decision value. Preserve this caution: A citation alone may not provide the minimum information needed for a valid ICSR.
A strong science note separates observation from interpretation. Keep search strings, dates, review decisions, full-text status and case links. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Keep search strings, dates, review decisions, full-text status and case links. Keep this boundary visible: A citation alone may not provide the minimum information needed for a valid ICSR.
The same event may be reported by a patient, clinician, programme and regulator. Demographics, dates, product, event and narrative clues support duplicate detection while privacy protections constrain matching.
The core discipline in duplicates can distort the safety picture is to preserve source context while acting on time. The same event may be reported by a patient, clinician, programme and regulator. Demographics, dates, product, event and narrative clues support duplicate detection while privacy protections constrain matching. Keep this boundary visible: Over-aggressive merging can combine different people; missed duplicates can inflate apparent frequency.
Try this
Classify five source scenarios for duplicates can distort the safety picture. Document match variables, uncertainty and the retained case hierarchy. Explain what changes the result. Keep this limit: Over-aggressive merging can combine different people; missed duplicates can inflate apparent frequency.
A strong science note separates observation from interpretation. Document match variables, uncertainty and the retained case hierarchy. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Document match variables, uncertainty and the retained case hierarchy. Keep this boundary visible: Over-aggressive merging can combine different people; missed duplicates can inflate apparent frequency.
CHAPTER 14 OF 17 · Strengthen the case
14. Follow-up should improve clinically important gaps
Reasonable follow-up seeks outcome, diagnosis, timing, exposure, tests, treatment and confounders. Priority should reflect seriousness, novelty, preventability and the value of missing information rather than a mechanical request for every field.
For follow-up should improve clinically important gaps, a valid case and a proven causal relationship are different conclusions. Reasonable follow-up seeks outcome, diagnosis, timing, exposure, tests, treatment and confounders. Priority should reflect seriousness, novelty, preventability and the value of missing information rather than a mechanical request for every field. Preserve this guardrail: Repeated contact can burden reporters and should respect consent and local requirements.
Try this
Build a day-zero timeline for follow-up should improve clinically important gaps. Rank questions by decision value and record each attempt and response. Include vendor and digital-platform handoffs. Respect this boundary: Repeated contact can burden reporters and should respect consent and local requirements.
A strong science note separates observation from interpretation. Rank questions by decision value and record each attempt and response. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Rank questions by decision value and record each attempt and response. Keep this boundary visible: Repeated contact can burden reporters and should respect consent and local requirements.
CHAPTER 15 OF 17 · Strengthen the case
15. Privacy and verification must work together
Case processing needs enough traceability to validate information and manage duplicates while limiting personal data to what is necessary. Access controls, secure transfer and retention rules protect reporters and patients.
A defensible decision about privacy and verification must work together records what was known, when it was known and which rule applied. Case processing needs enough traceability to validate information and manage duplicates while limiting personal data to what is necessary. Access controls, secure transfer and retention rules protect reporters and patients. Remember: De-identification should not erase information needed for legitimate safety obligations without a reasoned process.
Try this
Audit one post-approval case for privacy and verification must work together. Map every personal-data element to purpose, access, retention and protection. Prioritise follow-up by decision value. Preserve this caution: De-identification should not erase information needed for legitimate safety obligations without a reasoned process.
A strong science note separates observation from interpretation. Map every personal-data element to purpose, access, retention and protection. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Map every personal-data element to purpose, access, retention and protection. Keep this boundary visible: De-identification should not erase information needed for legitimate safety obligations without a reasoned process.
CHAPTER 16 OF 17 · Strengthen the case
16. Quality systems keep vendors and programmes aligned
Patient-support providers, market-research agencies and digital service vendors may receive safety information on behalf of a company. Agreements, training, intake channels, clock-start rules, reconciliation and oversight should make responsibilities clear.
The core discipline in quality systems keep vendors and programmes aligned is to preserve source context while acting on time. Patient-support providers, market-research agencies and digital service vendors may receive safety information on behalf of a company. Agreements, training, intake channels, clock-start rules, reconciliation and oversight should make responsibilities clear. Keep this boundary visible: Contracting work out does not remove the authorisation holder’s accountability.
Try this
Classify five source scenarios for quality systems keep vendors and programmes aligned. Test each partner with a sample case from receipt through submission and reconciliation. Explain what changes the result. Keep this limit: Contracting work out does not remove the authorisation holder’s accountability.
A strong science note separates observation from interpretation. Test each partner with a sample case from receipt through submission and reconciliation. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Test each partner with a sample case from receipt through submission and reconciliation. Keep this boundary visible: Contracting work out does not remove the authorisation holder’s accountability.
CHAPTER 17 OF 17 · Strengthen the case
17. A complete E2D(R1) receipt makes the decision reproducible
The receipt records source type, minimum criteria, dates, clock start, seriousness, expectedness, causality views, special situations, duplicates, follow-up, privacy controls, reporting decision and acknowledgement. It shows how raw contact became a managed case.
For a complete e2d(r1) receipt makes the decision reproducible, a valid case and a proven causal relationship are different conclusions. The receipt records source type, minimum criteria, dates, clock start, seriousness, expectedness, causality views, special situations, duplicates, follow-up, privacy controls, reporting decision and acknowledgement. It shows how raw contact became a managed case. Preserve this guardrail: Documentation supports consistent judgment but does not turn uncertain causality into fact.
Try this
Build a day-zero timeline for a complete e2d(r1) receipt makes the decision reproducible. Give the receipt to a second reviewer and ask whether they reach the same classification and deadline. Include vendor and digital-platform handoffs. Respect this boundary: Documentation supports consistent judgment but does not turn uncertain causality into fact.
A strong science note separates observation from interpretation. Give the receipt to a second reviewer and ask whether they reach the same classification and deadline. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Give the receipt to a second reviewer and ask whether they reach the same classification and deadline. Keep this boundary visible: Documentation supports consistent judgment but does not turn uncertain causality into fact.
E2D(R1) case-management map
| Question | Evidence to capture | Boundary to retain |
|---|---|---|
| Is there a valid case? | Reporter, patient, product and event | Missing data still need follow-up |
| What is the source? | Spontaneous, solicited, literature or digital context | Location alone is insufficient |
| What clock applies? | Receipt, recognition, day zero and regional rules | Internal delay does not reset time |
| How does it improve? | Duplicate control, follow-up, privacy and quality | Do not overstate causality |
Science learning becomes useful when a student can show where a claim came from, why it applies and where it stops. Continue with the eduKate Science Learning Hub, compare choices in the Education Hub, and connect these habits to career pathways built from subject capabilities.
E2D(R1) makes modern pharmacovigilance practical: listen across many channels, classify each source honestly, start the clock consistently and improve the case without losing the person or context behind it.
Primary sources and verification date
Source status checked 26 October 2026. FDA guidance describes the agency’s current thinking and does not replace applicable statutes, regulations or product-specific communication with FDA.
- FDA: ICH E2D(R1) post-approval safety data — Final Level 1 guidance, March 2026; docket FDA-2024-D-0803.
- FDA: Full E2D(R1) guidance PDF — Official definitions, source classification, case management and reporting standards.
- FDA: AEMS electronic submissions — Current E2D(R1) alignment and electronic reporting context, checked 26 October 2026.
